No connection

Search Results

ONCO vs WORX

ONCO
Onconetix, Inc.
BEARISH
Price
$0.76
Market Cap
$0.5M
Sector
Healthcare
AI Confidence
95%
WORX
SCWorx Corp.
BEARISH
Price
$1.00
Market Cap
$1.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ONCO
--
WORX
--
Forward P/E
ONCO
-0.9
WORX
--
P/B Ratio
ONCO
0.02
WORX
1.94
P/S Ratio
ONCO
0.67
WORX
0.37
EV/EBITDA
ONCO
0.73
WORX
0.39

Profitability

Gross Margin
ONCO
77.62%
WORX
31.96%
Operating Margin
ONCO
-422.06%
WORX
-25.01%
Profit Margin
ONCO
0.0%
WORX
-154.44%
ROE
ONCO
-115.46%
WORX
-76.35%
ROA
ONCO
-14.93%
WORX
-8.42%

Growth

Revenue Growth
ONCO
-57.4%
WORX
13.8%
Earnings Growth
ONCO
--
WORX
--

Financial Health

Debt/Equity
ONCO
0.0
WORX
0.02
Current Ratio
ONCO
0.66
WORX
2.72
Quick Ratio
ONCO
0.61
WORX
2.63

Dividends

Dividend Yield
ONCO
--
WORX
--
Payout Ratio
ONCO
0.0%
WORX
0.0%

AI Verdict

ONCO BEARISH

ONCO exhibits critical financial distress, anchored by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is in a catastrophic price collapse, falling from a 52-week high of $74.38 to $0.76, representing a near-total loss of market value. With a current ratio of 0.66 and revenue plummeting by 57.40% YoY, the firm faces an immediate liquidity crisis and a failing business model. The combination of extreme operating losses (-422.06% margin) and a bearish technical trend suggests a high probability of insolvency.

Strengths
High Gross Margin (77.62%) suggesting product value if costs were controlled
Low Price-to-Book ratio (0.02) indicating the stock trades far below book value
Low Price-to-Sales ratio (0.67)
Risks
Extreme liquidity risk with a Current Ratio of 0.66
Severe revenue contraction (-57.40% YoY)
Catastrophic price depreciation (-97.2% over 1 year)
WORX BEARISH

SCWorx Corp exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is experiencing a catastrophic price collapse, with a 5-year decline of 99.7% and a recent 1-month drop of 47.5%. Despite a low debt-to-equity ratio and modest revenue growth of 13.8%, the profit margin of -154.44% and an ROE of -76.35% demonstrate an unsustainable business model that is rapidly eroding shareholder equity.

Strengths
Low Debt/Equity ratio (0.02)
Positive YoY Revenue Growth (13.80%)
Current Ratio of 2.72 suggests short-term liquidity
Risks
Extreme negative profitability (Profit Margin -154.44%)
Severe capital erosion (5Y Change -99.7%)
Piotroski F-Score of 1/9 indicates failing financial health

Compare Another Pair

ONCO vs WORX: Head-to-Head Comparison

This page compares Onconetix, Inc. (ONCO) and SCWorx Corp. (WORX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile